Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial
Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optim...
Saved in:
Main Authors: | Guillaume Drevin (Author), Marie Briet (Author), Caroline Bazzoli (Author), Emmanuel Gyan (Author), Aline Schmidt (Author), Hervé Dombret (Author), Corentin Orvain (Author), Aurelien Giltat (Author), Christian Recher (Author), Norbert Ifrah (Author), Philippe Guardiola (Author), Mathilde Hunault-Berger (Author), Chadi Abbara (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature
by: Guillaume Drevin, et al.
Published: (2024) -
Altered Pharmacokinetics of Daunorubicin in Rats with CCl4-Induced Hepatic Injury
by: Min-Koo Choi, et al.
Published: (2007) -
Ancillary Tests
by: Pınar Zeyneloğlu, et al.
Published: (2023) -
Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats
by: Punniyakoti T. Veeravedu, et al.
Published: (2011) -
Individualized infliximab therapy: pharmacokinetic monitoring
by: Eugènia Santacana-Juncosa, et al.
Published: (2015)